"Designing Growth Strategies is in our DNA"

Familial Amyloid Polyneuropathy Therapeutics Market Size, Share & Industry Analysis By Drug Type (Inotersen, Tafamidis, Patisiran), By Disease Type (Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III)), By Gender Type (Male, Female), By Distribution Channel (Hospital Pharmacies, Retail pharmacies) Others and Regional Forecast, 2021-2028

Region : Global | Report ID: FBI102086 | Status : Ongoing

 

KEY MARKET INSIGHTS

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid polyneuropathy, is an inherited, progressive and a rare disease caused by the unusual deposits of amyloids or proteins around peripheral nerves and other tissues. FAP is considered to be very rare in most countries of the world. The incidence rate of the disease is estimated to be comapratively lower in developed countries such as the U.S. and several other European countries. In other regions of the world, the prevalence is comparatively higher.


Key Market Driver -

Rise in number of R&D activities pertaining to enhanced treatment solutions for familial amyloid polyneuropathy

Key Market Restraint -

Stringent government regulations for approval of such drugs


The familial amyloid polyneuropathy therapeutics market is estimated to witness substantial growth across the forecast period. High growth is attributable to increasing number of therapeutic drugs being approved for the treatment of the disease. Moreover, rising incidence of familial amyloid polyneuropathy disorder across various countries of the world is another major factor augmenting market growth. Additionally, increasing adoption rate of therapeutic drugs for treatment of the disease, owing to rising awarness among the population of emerging countries such as India, China and others will create new opportunities for the familial amyloid polyneuropathy market. Also, increasing number of companies operating in the market will further provide lucrative growth opportunities. Hence, the aforementioned factors will reflect a positive growth trajectory for the familial amyloid polyneuropathy therapeutics market across the forecast period.


However, high cost associated with the research & development and treatment activities might restrict market growth up to a certain extent. Also, stringent government norms related to approval of such drugs is another chief factor limiting market growth.


Market Segmentation:


By drug type, the market is segmented into inotersen, tafamidis, patisiran and others. Based on disease type, the market is segmented into Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III) and Familial Amyloid Polyneuropathy-IV (FAP-IV). Based on gender type, the familial amyloid polyneuropathy therapeutics market is bifurcated into male and female. Furthermore, the distribution channel is classified as hospital pharmacies, retail pharmacies and online pharmacies.


From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.


Key Players Covered:


The major companies in the global familial amyloid polyneuropathy therapeutics market report includes Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc., and others.   


Key Insights



  • Product Pipeline of the Therapeutic Drugs for Familial Amyloid Polyneuropathy

  • Prevalence Ratio of Familial Amyloid Polyneuropathy, Key Countries, 2018

  • New Product Launch, Key Players  

  • Product Approvals and Clinical Trial stage Data


Regional Analysis:


The global familial amyloid polyneuropathy therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is estimated to witness lucrative growth across the forecast period. High growth is attributed to increasing prevalence of familial amyloid polyneuropathy disorder across various countries of the Asia Pacific regions. North America, followed by Europe is expected to hold substantial amount of shares across 2018 to 2026, owing to growing number of market players operating in the regions.


To gain extensive insights into the market, Request for Customization


Moreover, Latin America and Middle East & Africa are projected to register a comparatively higher CAGR by the end of the forecast period, due to growing awareness among the population about the various benefits associated with familial amyloid polyneuropathy therapeutics, coupled with growing adoption rate of the drugs in these countries.


Segmentation






























 ATTRIBUTE


 DETAILS

By Drug Type




  • Inotersen

  • Tafamidis

  • Patisiran

  • Others



By Disease Type




  • Familial Amyloid Polyneuropathy-I (FAP-I)

  • Familial Amyloid Polyneuropathy-II (FAP-II)

  • Familial Amyloid Polyneuropathy-III (FAP-III)

  • Familial Amyloid Polyneuropathy-IV (FAP-IV)



By Gender Type




  • Male

  • Female



By Distribution Channel




  • Hospital Pharmacies

  • Retail pharmacies

  • Online Pharmacies



By Geography




  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



 Familial Amyloid Polyneuropathy Therapeutics Industry Developments



  • In July 2019, Alnylam Pharmaceuticals Inc., announced the Health Canada approval and immediate availability of ONPATTRO (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Such approvals allow the company to cover untapped markets, thus augmenting revenue growth.

  • In August 2017, Pfizer Inc. announced the successful analysis results of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with hereditary amyloid polyneuropathy and was well tolerated, with no unexpected side effects. Such approvals enabled the company to generate more revenue.


Familial Amyloid Polyneuropathy Therapeutics Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2020
  • 2017-2019

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Galemed
Ansell
Roche
Amgen
Jubilant

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X